Business
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22, 2026, in San Diego, California. These data include updated results from the TRUST-I and TRUST-II clinical studies highlighting the efficacy and safety of IBTROZI® (taletrectinib) for the treatment of ROS1-positi
About this update from Nuvation Bio Inc.
[{"type":"text","content":"Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to 50 months as of August 2025 data cutoff","length":240,"tagName":"p","attribs":{}},{"type":"text","content":"Presentations will also highlight new data on the efficacy and safety of taletrectinib in TKI-pretreated patients with ROS1+ NSCLC ","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, March 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22, 2026, in San Diego, California. These data include updated results from the TRUST-I and TRUST-II clinical studies highlighting the efficacy and safety of IBTROZI® (taletrectinib) for the treatment of ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in both tyrosine kinase inhibitor (TKI)-naïve and TKI-pretreated patients with ROS1+ NSCLC. The data to be presented represent nearly an additional year of follow-up from the data that supported IBTROZI's line-agnostic FDA approval in June 2025.","length":841,"tagName":"p"},{"type":"image","alt":"Nuvation Bio logo (PRNewsfoto/Nuvation Bio Inc.)","displaySize":"","headline":null,"caption":"Nuvation Bio logo (PRNewsfoto/Nuvation Bio Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":67,"url":"https://media.zenfs.com/en/prnewswire.com/eb40545e5f1eb1361b80045a4fef7988"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/orXZwjggSXGuOiVNNE1jOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/eb40545e5f1eb1361b80045a4fef7988","width":400,"height":67}},"href":"https://mma.prnewswire.com/media/2924210/Nuvation_Bio_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We're excited to present even longer-term follow-up data from our pivotal trials for IBTROZI, which further reinforce the depth and durability of responses in patients with advanced ROS1+ NSCLC across lines of therapy," said David Hung, M.D., Founder, President and Chief ...